Selected Publications

Elghawy O, Sussman JH, Yang AG, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome. JAMA Dermatol 161: 656-658, Jun 2025.

Yegya-Raman N, Plastaras JP, Wright CM, Chelius MR, Zhang S, Baron JA, Hubbeling H, Sim AJ, Robinson TJ, Jain MD, Imber BS, Fregonese B, Yahalom J, Ladbury C, Dandapani S, Pinnix CC, Gunther JR, Fang PQ, Wu SY, Dabaja BS, Yang JC, Chew J, Braunstein S, Sinha S, Denlinger N, Sun S, Terezakis SA, Sakthivel G, Constine LS, Chowdhry AK, Reagan PM, Burke S, Tseng YD, LaRiviere MJ, Maity A, Schuster SJ, Chong EA, Figura NB.: Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cells for B-Cell Lymphomas: An ILROG Multicenter Study. Blood Adv Apr 2025.

Elghawy O, Yang AG, Sussman JH, Thomas CJ, Carter JS, Landsburg DJ, Svoboda J, Kim E, Rook AH, Chung J, Villasenor-Park J, Plastaras JP, LaRiviere M, Hubbeling H, Chelius M, Nasta SD, Chong EA, Schuster SJ, Barta SK.: Retrospective cohort study of novel oral agents lenalidomide and duvelisib for relapsed or refractory mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 2025.

Hubbeling H, Leithner D, Silverman EA, Flynn J, Devlin S, Shah G, Fregonese B, Wills B, Bedmutha A, Alarcon Tomas A, Parascondola A, Saldia A, Landego I, Hajj C, Boardman AP, Dahi PB, Ghosh A, Giralt S, Lin RJ, Park J, Scordo M, Salles G, Yahalom J, Palomba ML, Schöder H, Perales MA, Shouval R, Imber BS.: Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma. Clin Cancer Res 30: 5083-5093, Nov 2024.

Cederquist GY, Schefflein J, Devlin SM, Shah GL, Shouval R, Hubbeling H, Tringale K, Alarcon Tomas A, Fregonese B, Hajj C, Boardman A, Luna De Abia A, Corona M, Cassanello G, Dahi PB, Lin RJ, Ghione P, Salles G, Perales MA, Palomba ML, Falchi L, Scordo M, Grommes C, Yahalom J, Imber BS.: CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas. Blood Adv 8: 5192-5199, Oct 2024.

Leithner D, Flynn JR, Devlin SM, Mauguen A, Fei T, Zeng S, Zheng J, Imber BS, Hubbeling H, Mayerhoefer ME, Bedmutha A, Luttwak E, Corona M, Dahi PB, Luna de Abia A, Landego I, Lin RJ, Palomba ML, Scordo M, Park JH, Tomas AA, Salles G, Lafontaine D, Michaud L, Shah GL, Perales MA, Shouval R, Schöder H.: Conventional and novel [(18)F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma. J Hematol Oncol 17: 21, Apr 2024.

Jiang C, Kim M, Han X, Chelius M, Hoover T, Kersun L, Reilly AF, Hubbeling H, Cummings E, Kurtz G, Hill-Kayser C, Plastaras JP, LaRiviere MJ.: Outcomes of proton therapy to infradiaphragmatic sites in pediatric patients with Hodgkin lymphoma. Pediatr Blood Cancer 2024.

Hubbeling HG, Silverman EA, Michaud L, Alarcon Tomas A, Shouval R, Flynn J, Devlin S, Wijetunga NA, Tringale KT, Batlevi C, Dahi P, Giralt S, Lin R, Park J, Scordo M, Sauter C, Shah G, Hajj C, Salles G, Schoder H, Palomba ML, Perales MA, Joachim Y, Imber BS.: Bridging Radiation Rapidly and Effectively Cytoreduces High-Risk Relapsed/Refractory Aggressive B Cell Lymphomas Prior to Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Therapy 29(4): 259.e1-259.e10, Apr 2023.

Miao E, Eichholz JE, Lebow ES, Flynn J, Zhang Z, Walch H, Hubbeling HG, Beal K, Moss NS, Yu K, Yang JT, Meng A, Kelly DW, Gomez DR, Rimner A, Schultz N, Drilon A, Imber BS, Pike LRG.: Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib. Lung Cancer 178: 57-65, Apr 2023.

Hubbeling HG, Choudhury N, Flynn J, Zhang Z, Falcon C, Rusch VW, Park BJ, Ziv E, Shaverdian N, Gelblum DY, Shepherd AF, Simone CB, Wu AJ, Gomez DR, Drilon A, Rimner A: Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ ROS1/ RET-Rearranged Lung Cancers. JCO Precision Oncology 6: e2200024, Oct 2022.